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the last 4 weeks?” In many languages a literal translation
would have been unclear and so the question was re-
placed by “how much of the time. . . .” Patient testing
showed different reactions to the instrument across coun-
tries and made it clear that terms such as “intercourse,”
“erection,” or “ejaculation” were not always understood
and required explanation. Prior to use in an international
trial, rigorous cultural adaptation was essential to pro-
duce cross-culturally valid language versions. Psychomet-
ric testing will be important to ensure similar relation-
ships among scales across countries. The comparison of
answer patterns across countries will clarify whether peo-
ple with similar health give equivalent answers.
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OBJECTIVE: To evaluate the economic effect of using
risperidone in nursing home residents with documented
behavioral and psychological signs and symptoms of de-
mentia (BPSSD).
METHODS: Based on 1995 data from a large nursing
home database, the average annual incremental cost of
care due to BPSSD was calculated for three diagnosis
groups (All Diagnoses, All Dementia, and Non-Demen-
tia). These costs, in 1997 US dollars, included increased
reimbursement resulting from transition to a higher level
of care and more frequent physician visits due to BPSSD.
These were compared with the cost of 1 mg per day ris-
peridone therapy.
RESULTS: BPSSD was documented in 13.5% of all nurs-
ing home residents—in 20% of those with dementia and
in 11% in those without dementia. The annual cost of
risperidone was estimated at $101, $148, and $85, re-
spectively, per patient in each group. The BD-related
costs considering all patients, regardless of behavioral
status, were $245, $383, and $195, respectively, per resi-
dent in each group. Risperidone was estimated to break
even if 42% of BPSSD-related transitions to a higher level
of care were prevented among all patients, 39% if only
demented patients are considered, and 44% for those
without dementia. With higher effectiveness, treatment
with risperidone would result in cost-savings. 
CONCLUSIONS: The use of risperidone in institutional-
ized patients with BPSSD should provide not only sub-
stantial relief of what can be a difficult-to-manage situa-
tion but also a favorable economic effect.
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MEDIPLUS AS A READILY AVAILABLE 
RESEARCH TOOL FOR DETERMINING THE 
INCIDENCE AND PREVALENCE OF MULTIPLE 
SCLEROSIS, ITS TREATMENT, PRESCRIPTION 
COSTS, AND REFERRALS IN UK PRACTICE
Grigas E, Carmichael R, Harrison P, McDermott J
Disease Treatment and Outcomes Group, IMS Health, 
Middlesex, UK
OBJECTIVES: The annual prevalence and annual inci-
dence of the diagnosis of multiple sclerosis (MS) in the UK
were determined, together with the therapies employed,
the associated costs, and the referrals to secondary care.
METHODS: This study used UKPCD, which contains
longitudinal records of nearly 2 million patients. Data are
captured daily from general practitioners who use the
AAH Meditel System 5 software as part of their standard
record keeping. Patients were selected according to the
primary care coding system, “Read,” (entered as a prob-
lem or problem-linked note code), from June 1997 to
June 1998. Therapies, prescription costs, and referrals
were extracted from these patients’ records.
RESULTS: The annual prevalence of MS was 62/100,000
(95% CI 58–66); the annual incidence was 7/100,000
(95% CI 6–8). A comparison of all therapies used to
manage MS patients showed apparent differences between
prevalent and incident patients, except in antidepressants
(36% both groups). Non-narcotic analgesics were pre-
scribed for 45% of prevalent patients and 32% of incident
patients. When therapy for prevalent patients was linked
to the Read code for MS, 33% of patients were prescribed
central muscle relaxants and 24% antidepressants. The
cost to the community for all prescribed products in the
study year was £159,508. The majority of note referrals
for both prevalent and incident patients was for neurolo-
gist care (20% and 40%) and physiotherapy (12% and
14%), respectively.
CONCLUSION: This study is an example of the use of an
automated, observational, primary care database such as
MediPlus in pharmacoeconomic and outcomes research.
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OBJECTIVE: Patients report in general to be dissatisfied
with headache treatment. A disease management pro-
gram was developed to improve the quality of headache
treatment of a general sick fund–insured population.
METHOD: Employees at a ship-building site (n  1996)
and their families were asked to fill in questionnaires if
they suffered from headache: the Short-Form 36, the Kiel
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Headache Questionnaire, and some additional items to
document medication and satisfaction with general ther-
apy. General information about management and preven-
tion of headache was offered to the 341 respondents suf-
fering from headache, as well as to physicians and
pharmacists. In a second survey, questionnaires were filled
out by the participants to record the impact of the pro-
gram.
RESULTS: Results from the first survey were reported by
Göbel et al. (Cephalalgia 17[1997]325). Of the 183 trace-
able initial respondents, 68.9% took part in the final sur-
vey: 29.1% of the participants reported an improvement
in health status; 43.1% stated fewer headaches; 38.9%
reported shorter headache attacks; 22.6% had better
knowledge to identify trigger factors; 21.0% reduced
their consumption of medication; and 41.9% learned an
active relaxation technique. Together with other exten-
sive healthcare measures initiated through the company,
there was a reduction of lost labor time due to illness.
CONCLUSION: It is possible to create a network between
employees, physicians, pharmacists, the sick fund, and the
pharmaceutical industry to successfully address the ques-
tion of headache management within a work-site environ-
ment. Unmet medical needs can be identified, and aware-
ness for intervention programs can be raised through
studies using general headache questionnaires. The infor-
mation of patients as well as physicians and pharmacists
reduced the burden of headache and improved the out-
comes of headache treatment. More collaborative efforts
to improve the unsatisfactory situation of headache pa-
tients and migraine patients are needed.
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The identification of cost components deriving from di-
rect and indirect consequences of disease is a fundamen-
tal step in conducting cost-effectiveness (CE) analysis. In
time-constrained efforts to collect CE data for inclusion
in a product’s commercial development dossier, little at-
tention is likely to be paid to fundamental research. Cou-
pled with other early research components, such as ex-
pert and/or patient interviews, a prior comprehensive
review of the literature can ensure a strong foundation on
which robust economic arguments could subsequently be
formulated.
OBJECTIVE: The objective of this research was to ex-
plore and define 1) cost drivers and 2) clinical endpoints
representing global treatment effectiveness in Parkinson’s
disease (PD).
METHODS: A review of the published literature in PD
was conducted, surveying elements including:
• Contemporary treatment options and costs;
• Clinical markers measuring progression;
• Indirect morbidity and related costs.
The geographic foci of the research were Germany and
the UK.
RESULTS: A global indicator of symptoms and compli-
cations of PD treatment is the Unified Parkinson’s Dis-
ease Rating Scale (UPDRS); significant events represent-
ing complications and co-morbidity include prevalence
and severity of motor complications—dyskinesias, de-
pression, dementia, and postural imbalance—leading to
falls and other accidents. Hospitalization accounts for
50% to 90% of costs of PD care in Germany and the UK,
followed by medication costs. The main determinants of
hospitalization rates are disease stage, akinetic type of dis-
ease and presence of motor fluctuations in spite of, as well
as in relation to, therapy. 
CONCLUSIONS: In collecting economic data for PD
treatment, the definitive demonstration of CE must in-
clude improved long-term efficacy, safety, and reduced
rates of direct and indirect resource utilization—in partic-
ular, hospitalization.
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OBJECTIVE: Patient outcome measures of health utility
and functional status were used to assess sensitivity to
drug treatment and its relationship to PD severity.
BACKGROUND: A multicenter trial in seven countries
compared the safety, tolerance, and efficacy of pramipex-
ole (to 4.5 mg) and bromocriptine (to 30 mg) in advanced
PD. Patients (N  247, 80 pramipexole, 84 bromocrip-
tine, 83 placebo) were male and female, in- and out-
patients, 30 years and older, with advanced idiopathic
PD (stages II-IV Hoehn and Yahr [H&Y]), with motor
fluctuations characterized as end-of-dose phenomena.
Each received individually optimized dosages of levo-
dopa. (Guttman et al., “Double-blind comparison of pra-
mipexole and bromocriptine treatment with placebo in
advanced Parkinson’s disease,” [Neurology 49:Oct 1997,
1060–1065]).
METHODS: Patients were treated for up to 9 months, 11
days: 1) ascending dose up to 3 months, 2) maintenance
dose for approximately 6 months, and 3) decreasing dose
up to 11 days. Primary efficacy endpoints were: UPDRS
II—Activities of Daily Living (ADLs), averaged over “on”
and “off” periods, and UPDRS III—Motor Examination
during “on” periods. Secondary endpoints included the
EuroQoL visual analog scale (VAS) and Functional Status
